CRL - Charles River Laboratories International Inc.
SNP 500


Strong Growth and Improving


based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 21.32%
Operating Income Growth is 32.33%
Net Income Growth is 31.56%
Earnings Per Share (EPS) Growth is 29.0%
Net Margin is 11.58%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.4
Debt Ratio is 0.65
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.41
Cash Flow is MODERATE
Cash from Operations Growth is 13.76%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Charles River Laboratories International Inc. (CRL) -
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
Industry - Research and Development in Biotechnology
Sector - Professional, Scientific, and Technical Services
CEO - James Foster
Employees - 17,000

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.